10/ 533,931

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1202txn

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JAN 02	STN pricing information for 2008 now available
NEWS 3	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS 4	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS 5	JAN 28	MARPAT searching enhanced
NEWS 6	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS 7	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS 8	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS 9	FEB 08	STN Express, Version 8.3, now available
NEWS 10	FEB 20	PCI now available as a replacement to DPCI
NEWS 11	FEB 25	IFIREF reloaded with enhancements
NEWS 12	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS 13	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS 14	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS 15	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS 16	MAR 31	CA/CAplus and CASREACT patent number format for U.S. applications updated
NEWS 17	MAR 31	LPCI now available as a replacement to LDPCI
NEWS 18	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 19	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS 20	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS 21	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS 22	APR 28	IMSRESEARCH reloaded with enhancements
NEWS 23	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS 24	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS 25	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS 26	JUN 06	KOREAPAT updated with 41,000 documents
NEWS 27	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS 28	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS 29	JUN 25	CA/CAplus and USPAT databases updated with IPC reclassification data
NEWS 30	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records

```
 NEWS 31  JUN 30  EMBASE, EMBAL, and LEMBASE updated with additional
                  options to display authors and affiliated
                  organizations
 NEWS 32  JUN 30  STN on the Web enhanced with new STN AnaVist
                  Assistant and BLAST plug-in
 NEWS 33  JUN 30  STN AnaVist enhanced with database content from EPFULL

 NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

 NEWS HOURS     STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN     Welcome Banner and News Items
 NEWS IPC8      For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 17:47:09 ON 24 JUL 2008

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.42       0.42

FILE 'REGISTRY' ENTERED AT 17:48:02 ON 24 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   23 JUL 2008  HIGHEST RN 1035697-56-3
DICTIONARY FILE UPDATES:  23 JUL 2008  HIGHEST RN 1035697-56-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10533391b.str
```






chain nodes :
11 21 22 31
ring nodes :
1 2 3 4 5 6 7 8 9 10 12 13 14 15 16 17 18 19 20 23 24 25 26
27 28
chain bonds :
2-31 4-21 7-11 11-12 21-22
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 12-13 12-17 13-14 14-15
15-16 16-17 16-18 17-20 18-19 19-20 23-24 23-28 24-25 25-26 26-27 27-28

exact/norm bonds :
2-31 4-21 7-11 11-12 21-22
exact bonds :
16-18 17-20 18-19 19-20 23-24 23-28 24-25 25-26 26-27 27-28
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-10 7-8 8-9 9-10 12-13 12-17 13-14 14-15
15-16 16-17
isolated ring systems :
containing 1 : 12 : 23 :

G1:i-Pr,[*1]

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:CLASS 22:CLASS 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom 28:Atom
31:CLASS

L1 STRUCTURE UPLOADED

=> d L1
L1 HAS NO ANSWERS
L1 STR



G1 i-Pr,[@1]

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 17:48:24 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -        1 TO ITERATE

100.0% PROCESSED         1 ITERATIONS                                 1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:            1 TO       80
PROJECTED ANSWERS:               1 TO       80

L2            1 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 17:48:29 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -       30 TO ITERATE

100.0% PROCESSED        30 ITERATIONS                                26 ANSWERS
SEARCH TIME: 00.00.01

L3           26 SEA SSS FUL L1

=> file capllus
'CAPLLUS' IS NOT A VALID FILE NAME
SESSION CONTINUES IN FILE 'REGISTRY'
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available.  If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   178.36     178.78

FILE 'CAPLUS' ENTERED AT 17:48:45 ON 24 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 24 Jul 2008 VOL 149 ISS 4
FILE LAST UPDATED: 23 Jul 2008 (20080723/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s l3
L4 4 L3

=> d l4 1- ibib abs hitstr
YOU HAVE REQUESTED DATA FROM 4 ANSWERS - CONTINUE? Y/(N):y

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:995977 CAPLUS
DOCUMENT NUMBER: 141:420417
TITLE: Therapeutic agents comprising an anti-angiogenic agent in combination with an Src inhibitor for use in normotensive treatment of angiogenesis
INVENTOR(S): Curwen, Jon Owen; Wedge, Stephen Robert
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 111 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004098604	A1	20041118	WO 2004-GB1939	20040504
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004237132	A1	20041118	AU 2004-237132	20040504
AU 2004237132	B2	20071018		
CA 2519930	A1	20041118	CA 2004-2519930	20040504

EP 1620104	A1	20060201	EP 2004-731049		20040504
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR					
BR 2004009742	A	20060509	BR 2004-9742		20040504
CN 1784232	A	20060607	CN 2004-80012089		20040504
JP 2006525304	T	20061109	JP 2006-506222		20040504
NO 2005004411	A	20051130	NO 2005-4411		20050923
US 20060223815	A1	20061005	US 2005-555389		20051103
MX 2005PA11858	A	20060217	MX 2005-PA11858		20051104
PRIORITY APPLN. INFO.:			GB 2003-10401	A	20030507
			WO 2004-GB1939	W	20040504

GI



I



II

AB The invention relates to the use of an anti-angiogenic agent, such as I (preparation given), in combination with an inhibitor of the Src family of non-receptor tyrosine kinases, such as the II (prepns. according to a previous patent given), in the manufacture of a medicament for use in the substantially normotensive treatment in a warm-blooded mammal such as a human being of a disease state associated with angiogenesis. The invention provides for the Src kinase inhibitor to be administered in an amount effective to counteract substantially the hypertension induced by the anti-angiogenic agent. Thus, 7-(2-chloroethoxy)-4-(6-chloro-2,3-methylenedioxyanilino)-5-isopropoxyquinazoline was coupled with 1-acetylpiperazine using KI in DMA to give I. The diastolic blood pressure profile of rats over a 24 h period after administration of a combination of 1.5 mg/kg of I and 25 mg/kg of II demonstrated that the contrasting blood pressure effects of the antiangiogenic agent and the Src kinase inhibitor were substantially counterbalanced.

IT 692054-06-1, 7-[2-(4-Acetylpiperazin-1-yl)ethoxy]-4-[(5-chloro-2,3-methylenedioxypyridin-4-yl)amino]-5-isopropoxyquinazoline
692054-28-7, 7-[2-(4-Acetylpiperazin-1-yl)ethoxy]-4-[(5-chloro-2,3-

methylenedioxypyridin-4-yl)amino]-5-[(tetrahydropyran-4-yl)oxy]quinazoline 692054-33-4 692054-44-7
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Src kinase inhibitor; therapeutic agents comprising an anti-angiogenic agent in combination with an Src inhibitor for use in normotensive treatment of angiogenesis)

RN 692054-06-1 CAPLUS
CN Ethanone, 1-[4-[2-[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-5-(1-methylethoxy)-7-quinazolinyl]oxy]ethyl]-1-piperazinyl]- (CA INDEX NAME)



RN 692054-28-7 CAPLUS
CN Ethanone, 1-[4-[2-[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-7-quinazolinyl]oxy]ethyl]-1-piperazinyl]- (CA INDEX NAME)



RN 692054-33-4 CAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-[2-[(3aR,6aS)-tetrahydro-5H-1,3-dioxolo[4,5-c]pyrrol-5-yl]ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 692054-44-7 CAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[2-[(3aR,6aS)-tetrahydro-5H-1,3-dioxolo[4,5-c]pyrrol-5-yl]ethoxy]-, rel- (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:857372 CAPLUS
DOCUMENT NUMBER: 141:350196
TITLE: Preparation of quinazoline derivatives as selective Src kinase inhibitors
INVENTOR(S): Curwen, Jon Owen
PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004087120	A2	20041014	WO 2004-GB1286	20040323
WO 2004087120	A3	20050127		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: GB 2003-7333 A 20030329

AB The invention relates to the use of quinazoline derivative as a Src kinase inhibitor in the production of a medicament for use in the prophylaxis or treatment of hypertension. More particularly, the invention concerns the anti-hypertensive use of a selective Src kinase inhibitor that possess less potent VEGF receptor tyrosine kinase inhibitory properties. The invention also relates to a combination product comprising a Src kinase inhibitor and one or more further anti-hypertensive agents and to the use of Src kinase inhibitors as primary regulators of cardiovascular disease and in the prevention of stroke. For example, 7-[2-(4-acetylpiperazin-1-yl)ethoxy]-4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-5-isopropoxyquinazoline administered to rats at 25 mg/kg p.o. on day 1 showed hypotensive effect of 25 mmHg on day 2.

IT 692054-44-7, 4-(5-Chloro-2,3-methylenedioxypyrid-4-ylamino)-7-[2-[(3RS,4SR)-3,4-methylenedioxypyrrolidin-1-yl]ethoxy]-5-isopropoxyquinazoline
RL: PAC (Pharmacological activity); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(preparation of quinazoline derivs. as selective Src kinase inhibitors and regulators of cardiovascular disease for prophylaxis or treatment of hypertension or for prevention of stroke)

RN 692054-44-7 CAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[2-[(3aR,6aS)-tetrahydro-5H-1,3-dioxolo[4,5-c]pyrrol-5-yl]ethoxy]-, rel- (CA INDEX NAME)

Relative stereochemistry.



IT 692054-06-1P, 7-[2-(4-Acetylpiperazin-1-yl)ethoxy]-4-(5-chloro-2,3-methylenedioxypyridin-4-ylamino)-5-isopropoxyquinazoline
692054-28-7P, 4-(5-Chloro-2,3-methylenedioxypyridin-4-ylamino)-7-[2-(4-acetylpiperazin-1-yl)ethoxy]-5-(tetrahydropyran-4-yloxy)quinazoline
692054-33-4P, 4-(5-Chloro-2,3-methylenedioxypyridin-4-ylamino)-5-(tetrahydropyran-4-yloxy)-7-[2-[(3RS,4SR)-3,4-methylenedioxypyrrolidin-1-yl]ethoxy]quinazoline

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinazoline derivs. as selective Src kinase inhibitors and regulators of cardiovascular disease for prophylaxis or treatment of hypertension or for prevention of stroke)

RN 692054-06-1 CAPLUS
CN Ethanone, 1-[4-[2-[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-5-(1-methylethoxy)-7-quinazolinyl]oxy]ethyl]-1-piperazinyl]- (CA INDEX NAME)



RN 692054-28-7 CAPLUS
CN Ethanone, 1-[4-[2-[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-7-quinazolinyl]oxy]ethyl]-1-piperazinyl]- (CA INDEX NAME)



RN 692054-33-4 CAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-[2-[(3aR,6aS)-tetrahydro-5H-1,3-dioxolo[4,5-c]pyrrol-5-yl]ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-, rel- (CA INDEX NAME)

Relative stereochemistry.



IT 692053-18-2P, 7-(2-Chloroethoxy)-4-(5-chloro-2,3-methylenedioxypyridin-4-ylamino)-5-tetrahydropyran-4-yloxyquinazoline
692053-23-9P, 7-(2-Chloroethoxy)-4-(5-chloro-2,3-methylenedioxypyridin-4-ylamino)-5-isopropoxyquinazoline
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(reactant; preparation of quinazoline derivs. as selective Src kinase inhibitors and regulators of cardiovascular disease for prophylaxis or treatment of hypertension or for prevention of stroke)

RN 692053-18-2 CAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-(2-chloroethoxy)-5-[(tetrahydro-2H-pyran-4-yl)oxy]- (CA INDEX NAME)



RN 692053-23-9 CAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-(2-chloroethoxy)-5-(1-methylethoxy)- (CA INDEX NAME)



L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:430753 CAPLUS
DOCUMENT NUMBER: 141:1220
TITLE: Preparation of quinazolines as Src family non-receptor tyrosine kinase inhibitors for use in combination therapy with gemcitabine for treatment and prophylaxis of pancreatic cancer
INVENTOR(S): Barge, Alan
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 75 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004043472	A1	20040527	WO 2003-GB4787	20031107
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2504666	A1	20040527	CA 2003-2504666	20031107
AU 2003279456	A1	20040603	AU 2003-279456	20031107
AU 2003279456	B2	20070517		
EP 1562612	A1	20050817	EP 2003-772404	20031107
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003016170	A	20050927	BR 2003-16170	20031107
CN 1711094	A	20051221	CN 2003-80103138	20031107
JP 2006508953	T	20060316	JP 2004-550784	20031107
NZ 539514	A	20071130	NZ 2003-539514	20031107
NO 2005002312	A	20050606	NO 2005-2312	20050511
ZA 2005003805	A	20060927	ZA 2005-3805	20050511
MX 2005PA05119	A	20050802	MX 2005-PA5119	20050512
US 20060142297	A1	20060629	US 2005-534721	20051020
PRIORITY APPLN. INFO.:			GB 2002-26434 A	20021113
			WO 2003-GB4787 W	20031107

GI



I

AB The invention concerns a combination comprising an inhibitor of Src kinase and the cytotoxic agent, gemcitabine, a pharmaceutical composition comprising such a combination, and its use in the treatment or prophylaxis of cancer, particularly of pancreatic cancer. Examples include prepns. for anilino- and (pyridylamino)quinazoline Src inhibitors (no Markush structure given) and bioassays demonstrating the synergistic effect of treating pancreatic cancer with a quinazoline Src inhibitor in combination with gemcitabine. For instance, 4-amino-5-chloro-2,3-methylenedioxypyridine was coupled with 4-chloro-7-(3-chloropropoxy)-6-methoxyquinazoline (preparation of reactants given) in the presence of sodium hexamethyldisilazane in THF to afford the (pyridylamino)quinazoline I. Nude mice were injected with pancreatic tumor cells derived from the COLO 357 human pancreatic cancer cell line and treated with gemcitabine, the Src inhibitor, 4-(2-chloro-5-methoxyanilino)-6-methoxy-7-(N-methylpiperidin-4-ylmethoxy)quinazoline, or a combination of the two. Evaluation for tumor growth and incidence of liver metastases showed that, compared with the weight of control tumors, tumor growth in animals treated with the combination was much reduced (1359 mg and 124 mg, resp.) to a level well below that achievable on the dosing of either gemcitabine or the Src inhibitor alone. In addition, there was no liver metastasis in the animals treated with the combination, whereas liver metastasis was present in 1/5 of the animals treated with gemcitabine alone.

IT 692053-18-2P, 7-(2-Chloroethoxy)-4-[(5-chloro-2,3-methylenedioxypyridin-4-yl)amino]-5-[(tetrahydropyran-4-yl)oxy]quinazoline 692053-23-9P, 7-(2-Chloroethoxy)-4-[(5-chloro-2,3-methylenedioxypyridin-4-yl)amino]-5-isopropoxyquinazoline 692053-39-7P, 4-[(5-Chloro-2,3-methylenedioxypyridin-4-yl)amino]-7-(3-chloropropoxy)-5-[(tetrahydropyran-4-yl)oxy]quinazoline 692053-44-4P, 4-[(5-Chloro-2,3-methylenedioxypyridin-4-yl)amino]-7-[(2,4-dimethoxybenzyl)oxy]-5-isopropoxyquinazoline 692053-55-7P, 7-(3-Chloropropoxy)-4-[(5-chloro-2,3-methylenedioxypyridin-4-yl)amino]-5-isopropoxyquinazoline 692055-28-0P, 5-Isopropoxy-7-[2-(piperazin-1-yl)ethoxy]-4-[(5-chloro-2,3-methylenedioxypyridin-4-yl)amino]quinazoline RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(antitumor agent; preparation of quinazoline-containing Src inhibitors for use
in synergistic combination with gemcitabine for treatment and prophylaxis of pancreatic cancer)

RN 692053-18-2 CAPLUS

CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-(2-chloroethoxy)-5-[(tetrahydro-2H-pyran-4-yl)oxy]- (CA INDEX NAME)



RN 692053-23-9 CAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-(2-chloroethoxy)-5-(1-methylethoxy)- (CA INDEX NAME)



RN 692053-39-7 CAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-(3-chloropropoxy)-5-[(tetrahydro-2H-pyran-4-yl)oxy]- (CA INDEX NAME)



RN 692053-44-4 CAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-[(2,4-dimethoxyphenyl)methoxy]-5-(1-methylethoxy)- (CA INDEX NAME)



RN 692053-55-7 CAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-(3-chloropropoxy)-5-(1-methylethoxy)- (CA INDEX NAME)



RN 692055-28-0 CAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[2-(1-piperazinyl)ethoxy]- (CA INDEX NAME)



IT 692053-49-9P, 4-[(5-Chloro-2,3-methylenedioxypyridin-4-yl)amino]-7-hydroxy-5-isopropoxyquinazoline 692053-72-8P, 7-[2-(4-Acetylpiperazin-1-yl)ethoxy]-4-[(2,3-methylenedioxypyridin-4-yl)amino]-5-[(tetrahydropyran-4-yl)oxy]quinazoline 692053-76-2P, 7-[2-(4-Acetylpiperazin-1-yl)ethoxy]-4-[(2,3-methylenedioxypyridin-4-yl)amino]-5-isopropoxyquinazoline 692053-82-0P, 4-[(5-Chloro-2,3-methylenedioxypyridin-4-yl)amino]-7-[2-[4-(2-dimethylaminoacetyl)piperazin-1-yl]ethoxy]-5-isopropoxyquinazoline

692054-06-1P, 5-Isopropoxy-7-[2-(4-acetylpiperazin-1-yl)ethoxy]-4-[(5-chloro-2,3-methylenedioxypyridin-4-yl)amino]quinazoline 692054-28-7P, 5-[(Tetrahydropyran-4-yl)oxy]-7-[2-(4-acetylpiperazin-1-yl)ethoxy]-4-[(5-chloro-2,3-methylenedioxypyridin-4-yl)amino]quinazoline 692054-33-4P 692054-44-7P 692055-04-2P, 5-[(Tetrahydropyran-4-yl)oxy]-7-[2-[4-(prop-2-ynyl)piperazin-1-yl]ethoxy]-4-[(5-chloro-2,3-methylenedioxypyridin-4-yl)amino]quinazoline 692055-10-0P, 5-[(Tetrahydropyran-4-yl)oxy]-7-[2-(morpholino)ethoxy]-4-[(5-chloro-2,3-methylenedioxypyridin-4-yl)amino]quinazoline 692055-16-6P, 5-[(Tetrahydropyran-4-yl)oxy]-7-[3-(morpholino)propoxy]-4-[(5-chloro-2,3-methylenedioxypyridin-4-yl)amino]quinazoline 692055-22-4P, 5-[(Tetrahydropyran-4-yl)oxy]-7-[3-[4-(prop-2-ynyl)piperazin-1-yl]propoxy]-4-[(5-chloro-2,3-methylenedioxypyridin-4-yl)amino]quinazoline 692055-34-8P, 5-Isopropoxy-7-[2-[4-(2-hydroxyethyl)piperazin-1-yl]ethoxy]-4-[(5-chloro-2,3-methylenedioxypyridin-4-yl)amino]quinazoline 692055-41-7P, 5-Isopropoxy-7-[2-(pyrrolidin-1-yl)ethoxy]-4-[(5-chloro-2,3-methylenedioxypyridin-4-yl)amino]quinazoline 692055-46-2P, 5-Isopropoxy-7-[2-(piperidino)ethoxy]-4-[(5-chloro-2,3-methylenedioxypyridin-4-yl)amino]quinazoline 692055-53-1P, 5-Isopropoxy-7-[2-(morpholino)ethoxy]-4-[(5-chloro-2,3-methylenedioxypyridin-4-yl)amino]quinazoline 692055-59-7P, 5-Isopropoxy-7-[2-[4-(prop-2-ynyl)piperazin-1-yl]ethoxy]-4-[(5-chloro-2,3-methylenedioxypyridin-4-yl)amino]quinazoline 692055-76-8P, 5-Isopropoxy-7-[2-(4-methylpiperazin-1-yl)ethoxy]-4-[(5-chloro-2,3-methylenedioxypyridin-4-yl)amino]quinazoline 692055-83-7P, 5-Isopropoxy-7-[3-(morpholino)propoxy]-4-[(5-chloro-2,3-methylenedioxypyridin-4-yl)amino]quinazoline
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antitumor agent; preparation of quinazoline-containing Src inhibitors for use
in synergistic combination with gemcitabine for treatment and prophylaxis of pancreatic cancer)

RN 692053-49-9 CAPLUS
CN 7-Quinazolinol, 4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-5-(1-methylethoxy)- (CA INDEX NAME)



RN 692053-72-8 CAPLUS
CN Ethanone, 1-[4-[2-[[4-(1,3-dioxolo[4,5-b]pyridin-7-ylamino)-5-[(tetrahydro-2H-pyran-4-yl)oxy]-7-quinazolinyl]oxy]ethyl]-1-piperazinyl]- (CA INDEX NAME)



RN 692053-76-2 CAPLUS
CN Ethanone, 1-[4-[2-[[4-(1,3-dioxolo[4,5-b]pyridin-7-ylamino)-5-(1-methylethoxy)-7-quinazolinyl]oxy]ethyl]-1-piperazinyl]- (CA INDEX NAME)



RN 692053-82-0 CAPLUS
CN Ethanone, 1-[4-[2-[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-5-(1-methylethoxy)-7-quinazolinyl]oxy]ethyl]-1-piperazinyl]-2-(dimethylamino)- (CA INDEX NAME)



RN 692054-06-1 CAPLUS
CN Ethanone, 1-[4-[2-[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-5-(1-methylethoxy)-7-quinazolinyl]oxy]ethyl]-1-piperazinyl]- (CA INDEX NAME)



RN 692054-28-7 CAPLUS
CN Ethanone, 1-[4-[2-[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-7-quinazolinyl]oxy]ethyl]-1-piperazinyl]- (CA INDEX NAME)



RN 692054-33-4 CAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-[2-[(3aR,6aS)-tetrahydro-5H-1,3-dioxolo[4,5-c]pyrrol-5-yl]ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 692054-44-7 CAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[2-[(3aR,6aS)-tetrahydro-5H-1,3-dioxolo[4,5-c]pyrrol-5-yl]ethoxy]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 692055-04-2 CAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-[2-[4-(2-propyn-1-yl)-1-piperazinyl]ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]- (CA INDEX NAME)



RN 692055-10-0 CAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-[2-(4-morpholinyl)ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]- (CA INDEX NAME)



RN 692055-16-6 CAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-[3-(4-morpholinyl)propoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]- (CA INDEX NAME)



RN 692055-22-4 CAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-[3-[4-(2-propyn-1-yl)-1-piperazinyl]propoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]- (CA INDEX NAME)



RN 692055-34-8 CAPLUS
CN 1-Piperazineethanol, 4-[2-[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-5-(1-methylethoxy)-7-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)



RN 692055-41-7 CAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[2-(1-pyrrolidinyl)ethoxy]- (CA INDEX NAME)



RN 692055-46-2 CAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[2-(1-piperidinyl)ethoxy]- (CA INDEX NAME)



RN 692055-53-1 CAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[2-(4-morpholinyl)ethoxy]- (CA INDEX NAME)



RN 692055-59-7 CAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[2-[4-(2-propyn-1-yl)-1-piperazinyl]ethoxy]- (CA INDEX NAME)



RN 692055-76-8 CAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[2-(4-methyl-1-piperazinyl)ethoxy]- (CA INDEX NAME)



RN 692055-83-7 CAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[3-(4-morpholinyl)propoxy]- (CA INDEX NAME)



IT 692060-97-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of quinazoline-containing Src inhibitors for use in
synergistic combination with gemcitabine for treatment and prophylaxis of pancreatic cancer)
RN 692060-97-2 CAPLUS
CN 7-Quinazolinol, 4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-5-(1-methylethoxy)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 692053-49-9
CMF C17 H15 Cl N4 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:414727 CAPLUS
DOCUMENT NUMBER: 140:423698
TITLE: Preparation of quinazoline derivatives as c-Src tyrosine kinase inhibitors
INVENTOR(S): Ple, Patrick
PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.; Astrazeneca Uk Limited
SOURCE: PCT Int. Appl., 124 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004041829	A1	20040521	WO 2003-GB4703	20031029

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2503371	A1	20040521	CA 2003-2503371		20031029
AU 2003278383	A1	20040607	AU 2003-278383		20031029
AU 2003278383	B2	20070614			
EP 1562955	A1	20050817	EP 2003-769689		20031029
EP 1562955	B1	20080227			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
BR 2003015756	A	20050906	BR 2003-15756		20031029
CN 1735617	A	20060215	CN 2003-80108194		20031029
JP 2006506463	T	20060223	JP 2005-502127		20031029
NZ 539408	A	20070928	NZ 2003-539408		20031029
AT 387451	T	20080315	AT 2003-769689		20031029
ES 2300619	T3	20080616	ES 2003-769689		20031029
IN 2005DN01534	A	20061229	IN 2005-DN1534		20050415
NO 2005001900	A	20050601	NO 2005-1900		20050419
ZA 2005003337	A	20060726	ZA 2005-3337		20050425
MX 2005PA04858	A	20050722	MX 2005-PA4858		20050504
US 20060122199	A1	20060608	US 2005-533931		20050504
PRIORITY APPLN. INFO.:			EP 2002-292736	A	20021104
			EP 2003-290900	A	20030410
			WO 2003-GB4703	W	20031029

OTHER SOURCE(S): MARPAT 140:423698
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. I [R1 = halo, CF3, cyano, isocyano, NO3, OH, SH, amino, formyl, carboxy, carbamoyl, alkyl, alkenyl, alkynyl, alkoxy, etc.; Z = O, SO, SO2, N(R2)2, or C(R2)2; R2 = H or alkyl; m = 0-3; R3 = halo, CF3, CN, NO2, OH, amino, carboxy, carbamoyl, alkyl, alkenyl, alkynyl, alkoxy, etc.; n =0-3] were prepared as c-Src tyrosine kinase inhibitors in the containment and/or treatment of solid tumor disease. For example, reaction of 4-amino-5-chloro-2,3-methylenedioxypyridine(preparation given) and 4-chloro-7-(3-chloropropoxy)-6-methoxyquinazoline (preparation given) yielded compound II.

IT 692053-18-2P 692053-23-9P 692053-39-7P
692053-44-4P 692053-49-9P 692053-55-7P
692055-28-0P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of quinazoline derivs. as c-Src tyrosine kinase inhibitors)
RN 692053-18-2 CAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-(2-chloroethoxy)-5-[(tetrahydro-2H-pyran-4-yl)oxy]- (CA INDEX NAME)



RN 692053-23-9 CAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-(2-chloroethoxy)-5-(1-methylethoxy)- (CA INDEX NAME)



RN 692053-39-7 CAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-(3-chloropropoxy)-5-[(tetrahydro-2H-pyran-4-yl)oxy]- (CA INDEX NAME)



RN 692053-44-4 CAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-[(2,4-dimethoxyphenyl)methoxy]-5-(1-methylethoxy)- (CA INDEX NAME)



RN 692053-49-9 CAPLUS
CN 7-Quinazolinol, 4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-5-(1-methylethoxy)- (CA INDEX NAME)



RN 692053-55-7 CAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-(3-chloropropoxy)-5-(1-methylethoxy)- (CA INDEX NAME)



RN 692055-28-0 CAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[2-(1-piperazinyl)ethoxy]- (CA INDEX NAME)



IT 692053-72-8P 692053-76-2P 692053-82-0P
692054-06-1P 692054-28-7P 692054-33-4P
692054-44-7P 692055-04-2P 692055-10-0P
692055-16-6P 692055-22-4P 692055-34-8P
692055-41-7P 692055-46-2P 692055-53-1P
692055-59-7P 692055-76-8P 692055-83-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of quinazoline derivs. as c-Src tyrosine kinase inhibitors)

RN 692053-72-8 CAPLUS

CN Ethanone, 1-[4-[2-[[4-(1,3-dioxolo[4,5-b]pyridin-7-ylamino)-5-[(tetrahydro-2H-pyran-4-yl)oxy]-7-quinazolinyl]oxy]ethyl]-1-piperazinyl]- (CA INDEX NAME)



RN 692053-76-2 CAPLUS

CN Ethanone, 1-[4-[2-[[4-(1,3-dioxolo[4,5-b]pyridin-7-ylamino)-5-(1-methylethoxy)-7-quinazolinyl]oxy]ethyl]-1-piperazinyl]- (CA INDEX NAME)



RN 692053-82-0 CAPLUS
CN Ethanone, 1-[4-[2-[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-5-(1-methylethoxy)-7-quinazolinyl]oxy]ethyl]-1-piperazinyl]-2-(dimethylamino)- (CA INDEX NAME)



RN 692054-06-1 CAPLUS
CN Ethanone, 1-[4-[2-[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-5-(1-methylethoxy)-7-quinazolinyl]oxy]ethyl]-1-piperazinyl]- (CA INDEX NAME)



RN 692054-28-7 CAPLUS
CN Ethanone, 1-[4-[2-[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-7-quinazolinyl]oxy]ethyl]-1-piperazinyl]- (CA INDEX NAME)



RN 692054-33-4 CAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-[2-

[(3aR,6aS)-tetrahydro-5H-1,3-dioxolo[4,5-c]pyrrol-5-yl]ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 692054-44-7 CAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[2-[(3aR,6aS)-tetrahydro-5H-1,3-dioxolo[4,5-c]pyrrol-5-yl]ethoxy]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 692055-04-2 CAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-[2-[4-(2-propyn-1-yl)-1-piperazinyl]ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]- (CA INDEX NAME)



RN 692055-10-0 CAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-[2-(4-morpholinyl)ethoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]- (CA INDEX NAME)



RN 692055-16-6 CAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-[3-(4-morpholinyl)propoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]- (CA INDEX NAME)



RN 692055-22-4 CAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-7-[3-[4-(2-propyn-1-yl)-1-piperazinyl]propoxy]-5-[(tetrahydro-2H-pyran-4-yl)oxy]- (CA INDEX NAME)



RN 692055-34-8 CAPLUS
CN 1-Piperazineethanol, 4-[2-[[4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-5-(1-methylethoxy)-7-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)



RN 692055-41-7 CAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[2-(1-pyrrolidinyl)ethoxy]- (CA INDEX NAME)



RN 692055-46-2 CAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[2-(1-piperidinyl)ethoxy]- (CA INDEX NAME)



RN 692055-53-1 CAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[2-(4-morpholinyl)ethoxy]- (CA INDEX NAME)



RN 692055-59-7 CAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[2-[4-(2-propyn-1-yl)-1-piperazinyl]ethoxy]- (CA INDEX NAME)



RN 692055-76-8 CAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[2-(4-methyl-1-piperazinyl)ethoxy]- (CA INDEX NAME)



RN 692055-83-7 CAPLUS
CN 4-Quinazolinamine, N-(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)-5-(1-methylethoxy)-7-[3-(4-morpholinyl)propoxy]- (CA INDEX NAME)



IT 692060-97-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of quinazoline derivs. as c-Src tyrosine kinase inhibitors)
RN 692060-97-2 CAPLUS
CN 7-Quinazolinol, 4-[(6-chloro-1,3-dioxolo[4,5-b]pyridin-7-yl)amino]-5-(1-methylethoxy)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 692053-49-9
CMF C17 H15 Cl N4 O4



CM 2

CRN 76-05-1
CMF C2 H F3 O2

=> d his

(FILE 'HOME' ENTERED AT 17:47:09 ON 24 JUL 2008)

```
     FILE 'REGISTRY' ENTERED AT 17:48:02 ON 24 JUL 2008
L1                STRUCTURE UPLOADED
L2              1 S L1
L3             26 S L1 FULL

     FILE 'CAPLUS' ENTERED AT 17:48:45 ON 24 JUL 2008
L4              4 S L3

=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    22.28     201.06

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -3.20      -3.20

STN INTERNATIONAL LOGOFF AT 17:49:22 ON 24 JUL 2008
```